Lonza Launches New Capsule to Deliver Acid-Sensitive Active Pharmaceutical Ingredients to the Intestine
Lonza meets pressing market need by launching first ever coating-free capsule to support intestinal delivery of acid-sen…
Lonza meets pressing market need by launching first ever coating-free capsule to support intestinal delivery of acid-sen…
In H1 2022, Lonza delivers CHF 3 billion sales and 16.8%1 CER sales growth CHF 987 million CORE EBITDA resulted in a mar…
. Agreement initiates process for future acquisition of Lonza sites in Ploermel (FR) and Edinburgh (UK) allowing NextP…
Due to COVID-19, Lonza provides the following update outside of the regular reporting cycle: Group net sales reache…
Double-digit sales growth delivered by Pharma Biotech & Nutrition (LPBN) segment H1 headwinds in Specialty Ingredients (…
Continued positive momentum in Pharma Biotech & Nutrition All investments in healthcare businesses progressing as planne…
Lonza delivered its Full-Year 2018 results with sales of CHF 5.5 billion at a record 27.3% CORE EBITDA margin for Lo…
Businesses in Pharma & Biotech and in Consumer Health – including capsule and combined ingredient and dosage form offeri…
. Strategic Advantages Lonza to acquire Capsugel for USD 5.5 billion, including refinancing of existing Capsugel debt…